Explores Behemoth Labz GLP‑1 nasal formulation's structural design, analytic insights, and intranasal incretin research relevance in preclinical metabolic ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...

A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a routine place for health ...

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Shares of Eli Lilly & Co. (LLY) were tumbling in early trading Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations. The data ...

Shares of Eli Lilly and Co. (LLY) tumbled 12.8% in premarket trading Thursday, toward its biggest one-day selloff in 26 years, after the drug giant disclosed late-stage trial data for its oral ...

He noted that the two types of medications have different strengths: SGLT2 inhibitors are particularly good at protecting ...